Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy
01 juin 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, June 01, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis
18 mai 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Grant provides $1.1 million in non-dilutive funding for 2021 Nes Ziona, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage...
Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors
22 mars 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting...
Enlivex Announces Upcoming Virtual Investor Conference Participations
09 mars 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies
08 mars 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors
01 mars 2021 07h55 HE
|
Enlivex Therapeutics Ltd
-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor...
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy
22 févr. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares
18 févr. 2021 08h00 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...
Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy
16 févr. 2021 08h30 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
12 févr. 2021 17h21 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...